title: Treatment of malignant Leydig cell tumor.
abstract: Malignant Leydig cell tumors (LCT) are rare. Only 32 cases of malignant LCT (as evidenced by metastatic spread) were reported. Generally metastatic spread occurs within 2 years of the primary LCT, and the patient dies within 2 years of the discovery of metastatic disease. The tumor is highly resistant to both radiation and chemotherapy. It also has a great propensity for recurring after surgical resection. A case is reported of a patient whose metastatic disease occurred 8 years after his primary LCT had been resected. He was treated with doxorubicin and mitotane without response. The clinical features of this case are highlighted, and a review of the literature describing treatment of this rare disease is presented.
authors.affiliation: Department of Medical Oncology, Madigan Army Medical Center, Tacoma, Washington 98431.
authors.forename: K A
authors.initials: KA
authors.lastname: Bertram
authors.forename: B
authors.initials: B
authors.lastname: Bratloff
authors.forename: G F
authors.initials: GF
authors.lastname: Hodges
authors.forename: H
authors.initials: H
authors.lastname: Davidson
mesh_terms: D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007984:Leydig Cell Tumor / Q000556:secondary* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D008939:Mitotane / Q000627:therapeutic use; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000556:secondary*; D013736:Testicular Neoplasms / Q000473:pathology
chemical_list: D008939:Mitotane; D004317:Doxorubicin